Art. 37 Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 20…

End of a clinical trial, temporary halt and early termination of a clinical trial and submission of the results

In forcesince 16 Apr 2014cited 4×
1.

The sponsor shall notify each Member State concerned of the end of a clinical trial in relation to that Member State through the EU portal.

That notification shall be made within 15 days from the end of the clinical trial in relation to that Member State.

2.

The sponsor shall notify each Member State concerned of the end of a clinical trial in all Member States concerned through the EU portal.

That notification shall be made within 15 days from the end of the clinical trial in the last Member State concerned.

3.

The sponsor shall notify each Member State concerned of the end of a clinical trial in all Member States concerned and in all third countries in which the clinical trial has been conducted through the EU portal.

That notification shall be made within 15 days from the end of the clinical trial in the last of the Member States concerned and third countries in which the clinical trial has been conducted.

4.

Irrespective of the outcome of a clinical trial, within one year from the end of a clinical trial in all Member States concerned, the sponsor shall submit to the EU database a summary of the results of the clinical trial. The content of that summary is set out in Annex IV.

It shall be accompanied by a summary written in a manner that is understandable to laypersons. The content of that summary is set out in Annex V.

However, where, for scientific reasons detailed in the protocol, it is not possible to submit a summary of the results within one year, the summary of results shall be submitted as soon as it is available. In this case, the protocol shall specify when the results are going to be submitted, together with a justification.

In addition to the summary of the results, where the clinical trial was intended to be used for obtaining a marketing authorisation for the investigational medicinal product, the applicant for marketing authorisation shall submit to the EU database the clinical study report within 30 days after the day the marketing authorisation has been granted, the procedure for granting the marketing authorisation has been completed, or the applicant for marketing authorisation has withdrawn the application.

For cases where the sponsor decides to share raw data on a voluntary basis, the Commission shall produce guidelines for the formatting and sharing of those data.

5.

The sponsor shall notify each Member State concerned of a temporary halt of a clinical trial in all Member States concerned for reasons not affecting the benefit-risk balance through the EU portal.

That notification shall be made within 15 days from the temporary halt of the clinical trial in all Member States concerned and shall include the reasons for such action.

6.

When a temporarily halted clinical trial referred to in paragraph 5 is resumed the sponsor shall notify each Member State concerned through the EU portal.

That notification shall be made within 15 days from the restart of the temporarily halted clinical trial in all Member States concerned.

7.

If a temporarily halted clinical trial is not resumed within two years, the expiry date of this period or the date of the decision of the sponsor not to resume the clinical trial, whichever is earlier, shall be deemed to be the date of the end of the clinical trial. In the case of early termination of the clinical trial, the date of the early termination shall be deemed to be the date of the end of the clinical trial.

In the case of early termination of the clinical trial for reasons not affecting the benefit-risk balance, the sponsor shall notify each Member State concerned through the EU portal of the reasons for such action and, when appropriate, follow-up measures for the subjects.

8.

Without prejudice to paragraph 4, where the clinical trial protocol provides for an intermediate data analysis date prior to the end of the clinical trial, and the respective results of the clinical trial are available, a summary of those results shall be submitted to the EU database within one year of the intermediate data analysis date.

  • Code de la santé publiquel1128-12Law

    Le non-respect des articles 37, 42, 43 et 93 du règlement européen (UE) n° 536/2014 du Parlement européen du 16 avril 2014 relatif aux essais cliniques de médicaments sur la communication d'informations destinées à être mise à la …

  • Regulation (EU) 2022/12317Law

    … определен от Агенцията, който е по-кратък от срока, определен в член 37 от Регламент (ЕС) № 536/2014. 2. Когато лекарствен продукт, който е …

  • Order of the Vice-President of the Court of 1 March 2017. European Medicines Agency (EMA) v PTC Therapeutics International Ltd.Decision

    Secondly, it is clear from Article 37(4), Articles 80 and 81 and recital 67 of Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing …

    1 Mar 2017 · 62016CO0513

  • Judgment of the General Court (Second Chamber) of 25 September 2018. Amicus Therapeutics UK Ltd and Amicus Therapeutics, Inc. v European MedDecision

    In support of the contested decision and in rejecting the application of a general presumption, the EMA referred to Article 4(6) of Regulation No 1049/2001 according to which access to the whole of the document requested could be refused …

    25 Sep 2018 · 62017TJ0033